OPRX - オプティマイザ―Rx （OptimizeRx Corporation）

OptimizeRx is an exciting opportunity for investors who want to gain exposure to a growing market, which is the pharma ad spending.

OptimizeRx (OPRX) has announced a share repurchase program to buyback up to $15M of its outstanding common stock.The announcement follows the health technology company''s fourth…

ROCHESTER, Mich., March 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $15 million of its outstanding common stock.

Point-of-care technology solutions provider, OptimizeRx (OPRX) announced a multi-million-dollar, three-year agreement with a leading Hub services company.It will leverage…

OptimizeRx Corporation (NASDAQ:NASDAQ:OPRX) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ETCompany ParticipantsWill Febbo - CEOEd Stelmakh - CFO and COOSteve Silvestro - Chief…

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses,

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […]

As of Wednesday, OptimizeRx Corporation’s (NASDAQ:OPRX) stock closed at $17.77, up from $14.52 the previous day. While OptimizeRx Corporation has overperformed by 22.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPRX fell by -79.30%, with highs and lows ranging from $93.67 to $13.33, whereas the […]

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) shares climbed 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $450 million in milestone payments for the pancreatic cancer treatment. Outset Medical, Inc. (NASDAQ: OM ) surged 36.1% to $15.61 after the company reported better-than-expected Q3 results. OptimizeRx Corporation (NASDAQ: OPRX ) climbed 28% to $18.58 following better-than-expected Q3 results. Health Catalyst, Inc. (NASDAQ: HCAT ) rose 23% to $7.95 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance above analyst estimates. Vivint Smart Home, Inc. (NYSE: VVNT ) gained 21.4% to $8.50 after the company posted upbeat quarterly sales and raised FY22 revenue guidance. LiveRamp Holdings, Inc. (NYSE: RAMP ) rose 21% to $18.91 after the company reported better-than-expected Q2 results and issued strong guidance.

OptimizeRx Corporation (NASDAQ:NASDAQ:OPRX) Q3 2022 Earnings Conference Call November 8, 2022 16:30 ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief…

OptimizeRx (OPRX) has announced a partnership with Cooler Screens, a media and merchandising platform that brings the best aspects of in-store digital advertising into the…

In last trading session, OptimizeRx Corporation (NASDAQ:OPRX) saw 0.7 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $20.55 trading at -$3.81 or -15.64% at ring of the bell on the day assigns it a market valuation of $355.10M. That closing price of OPRX’s stock is at … With -3.8% Distance From Low, Is OptimizeRx Corporation (NASDAQ:OPRX) Poised For More Gains? Read More »

SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX ) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embedded messaging network and enjoys a solid financial profile of 30%+ top-line growth and mid-teens adjusted EBITDA margins. Despite this, the valuation is cheap. The stock currently trades at an ~2.5 turn discount to pharma digital … Full story available on Benzinga.com

OptimizeRx has strong network of large customers with a competitive advantage. Click here to see OPRX''s growth catalysts, risks, and my PT for OPRX stock.

The following slide deck was published by OptimizeRx Corporation in conjunction with this event.